/

BDTX

Black Diamond Therapeutics, IncAfter hours

1.68−0.09 −5.08%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.68 0.00%

Open

1.76

Prev close

1.77

Day range

1.601.77

52-week range

1.604.94

Volume

1.14M1.87×

Mkt cap

96.27M

P/E ttm

—

Fwd P/E

-1.68

EPS ttm

-0.7500

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−65.99%

Price Chart

Yahoo Finance · delayed

BDTXOct 13, 2026O 1.76H 1.77L 1.60C 1.68−0.09 (−5.08%)Vol 1.14M

SMA 501.99
SMA 2002.24

1Y change −58.92% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BDTX Black Diamond Therapeutics, Inc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.67%
1 month: −15.15%
3 months: −9.68%
6 months: −36.84%
Year to date: −30.86%
1 year: −55.79%

Valuation & ownership

Market cap: 96.27M
Enterprise value: 8.16M
P/E (ttm): —
Forward P/E: -1.68
PEG ratio: —
Price / book: 1.00
Price / sales (ttm): —
EV / EBITDA: -0.18
EPS (ttm): -0.7500
EPS (forward): -1.00
Beta (5y monthly): 3.33
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 57.30M
Float: 52.51M
Short % of float: 11.95%
Short ratio (days): 8.17
Held by insiders: 0.66%
Held by institutions: 72.59%
Avg volume (3m): 607.76K
50-day average: 1.99
200-day average: 2.25
52-week change: −55.79%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 31.6
vs 50-day SMA: −15.63%
vs 200-day SMA: −25.08%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.51%
Realised vol (20d, ann.): 41.8%
From 52-week high: −65.99%
From 52-week low: +5.00%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

10.00

+495.24% implied

Low 8.00Median 10.00High 14.00

Recommendation trend

Now7 / 1 / 0
1m ago7 / 1 / 0

DES

About Black Diamond Therapeutics, Inc

Yahoo Finance profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 21
Headquarters: Cambridge, MA, United States
Website: blackdiamondtherapeutics.com
Officers: Dr. Mark A. Velleca M.D., Ph.D. CEO, President & Chairman
Mr. Brent Hatzis-Schoch Esq., J.D. COO & General Counsel

SEAS

Seasonality · BDTX

2020–2026 · monthly returns

Strongest month Jun +38.03%Weakest month Feb −11.66%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	2.5	-0.8	-13.8	24.4	-16.2	-16.7	-8.6	24.3	-10.2	-10.9			−30.9%
2025	22.4	-23.3	-22.9	9.7	29.4	12.7	7.3	3.4	37.8	2.1	-1.3	-36.4	+13.6%
2024	36.7	34.0	-1.5	9.9	-14.2	-2.5	30.7	0.2	-28.7	-37.0	-3.3	-19.2	−23.8%
2023	66.7	-41.0	6.8	-24.3	30.1	171.5	-26.1	-9.7	-14.8	-34.5	24.5	20.1	+56.1%
2022	-21.8	-24.7	-11.8	-12.3	-30.5	45.6	42.3	-8.9	-47.0	36.7	-8.7	-14.7	−66.2%
2021	-22.7	13.0	-13.4	9.8	-50.8	-7.1	-21.6	5.6	-16.2	-9.5	-21.7	-11.2	−83.4%
2020		-28.0	-7.6	48.5	5.4	8.0	-34.0	3.4	5.1	4.2	5.8	-3.9	−14.5%

INSD

Insider Activity · BDTX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 17, 2026	Behbahani AliDirector	Stock Award(Grant) at price 1.93 per share.	7.7K	$14.88K
Sep 17, 2026	Raman PrakashDirector	Stock Award(Grant) at price 1.93 per share.	6.8K	$13.13K
Jun 17, 2026	Behbahani AliDirector	Stock Award(Grant) at price 1.66 per share.	9K	$14.88K
Jun 17, 2026	Raman PrakashDirector	Stock Award(Grant) at price 1.66 per share.	7.9K	$13.13K
Mar 19, 2026	Behbahani AliDirector	Stock Award(Grant) at price 2.15 per share.	6.9K	$14.88K
Mar 19, 2026	Raman PrakashDirector	Stock Award(Grant) at price 2.15 per share.	6.1K	$13.13K
Dec 11, 2025	Behbahani AliDirector	Stock Award(Grant) at price 2.76 per share.	5.2K	$14.37K
Dec 11, 2025	Raman PrakashDirector	Stock Award(Grant) at price 2.76 per share.	4.7K	$12.88K
Sep 18, 2025	Behbahani AliDirector	Stock Award(Grant) at price 3.35 per share.	4.3K	$14.38K
Sep 18, 2025	Raman PrakashDirector	Stock Award(Grant) at price 3.35 per share.	3.8K	$12.87K
Jun 19, 2025	Behbahani AliDirector	Stock Award(Grant) at price 2.33 per share.	6.2K	$14.38K
Jun 19, 2025	Raman PrakashDirector	Stock Award(Grant) at price 2.33 per share.	5.5K	$12.88K
Mar 20, 2025	Behbahani AliDirector	Stock Award(Grant) at price 1.88 per share.	7.6K	$14.37K
Mar 20, 2025	Raman PrakashDirector	Stock Award(Grant) at price 1.88 per share.	6.8K	$12.87K
Mar 18, 2025	Biotech Growth N.V.Beneficial Owner of more than 10% of a Class of Security	Sale at price 1.72 - 2.00 per share.	5.78M	$10.71M
Jan 29, 2025	Hatzis-Schoch BrentChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	75K	—
Jan 29, 2025	Yurasov SergeyOfficer	Stock Award(Grant) at price 0.00 per share.	75K	—
Jan 29, 2025	Velleca Mark A.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	75K	—
Jan 29, 2025	Buck Elizabeth Ph.D.Officer	Stock Award(Grant) at price 0.00 per share.	75K	—
Jan 29, 2025	Jones ErikaOfficer	Stock Award(Grant) at price 0.00 per share.	75K	—

13F

Investors Holding BDTX

latest 13F filings of 29 followed managers

Investors holding BDTX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$3.6M	0.00%	1.96M	+19%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

BDTX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BDTX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Black Diamond Therapeutics, Inc

Seasonality · BDTX

Insider Activity · BDTX

Congress Trades · BDTX

Investors Holding BDTX

Investors Holding BDTX

Congress Trades · BDTX

Insider Activity · BDTX

Seasonality · BDTX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Black Diamond Therapeutics, Inc

Financial Snapshot

Earnings & Dividends

News